← Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Press Releases
Date | Press release |
---|---|
2025-05-01 05:45:00 | June 3, 2025 Deadline: Contact The Gross Law Firm To Join Class Action Suit Against Abbv New york , may 1, 2025 /prnewswire/ -- the gross law firm issues the following notice to shareholders of cerevel therapeutics holdings, inc. (nyse: abbv). shareholders who purchased shares of abbv during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
2025-04-29 13:18:00 | Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors Of The Pending Class Action Lawsuit With A Lead Plaintiff Deadline Of June 3, 2025 – Abbv New york, april 29, 2025 (globe newswire) -- levi & korsinsky, llp notifies investors in cerevel therapeutics holdings, inc. (\"cerevel therapeutics holdings, inc.\" or the \"company\") (nyse: abbv) of a class action securities lawsuit. |
2025-04-29 07:45:00 | Shareholders That Lost Money On Cerevel Therapeutics Holdings, Inc. (abbv) Should Contact Levi & Korsinsky About Pending Class Action - Abbv New york, ny / access newswire / april 29, 2025 / if you suffered a loss on your cerevel therapeutics holdings, inc. (nyse:abbv) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=145953&wire=1 or contact joseph e. levi, esq. |
2025-04-29 07:30:00 | Rinvoq® (upadacitinib) Receives U.s. Fda Approval For Giant Cell Arteritis (gca) – rinvoq (upadacitinib) is now the first and only oral janus kinase (jak) inhibitor approved for the treatment of gca in adults – also known as temporal arteritis, gca is the most common vasculitis affecting adults in western countries 2 – this marks the ninth approved indication for rinvoq in the u.s., across rheumatology, gastroenterology, and dermatology1 north chicago, ill. , april 29, 2025 /prnewswire/ -- abbvie (nyse: abbv) today announced the u.s. food and drug administration (fda) has approved rinvoq® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (gca).1 this comes after the european commission recently granted marketing authorization of rinvoq for the treatment of gca in adult patients. |
2025-04-29 05:45:00 | Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors Of The Pending Class Action Lawsuit With A Lead Plaintiff Deadline Of June 3, 2025 - Abbv New york , april 29, 2025 /prnewswire/ -- levi & korsinsky, llp notifies investors in cerevel therapeutics holdings, inc. (\"cerevel therapeutics holdings, inc.\" or the \"company\") (nyse: abbv) of a class action securities lawsuit. class definition: the lawsuit seeks to recover losses on behalf of cerevel therapeutics holdings, inc. investors who were adversely affected by alleged securities fraud. |
2025-04-28 12:44:00 |
|
2025-04-28 05:45:00 |
|
2025-04-25 08:00:00 |
|
2025-04-25 07:43:00 |
|
2025-04-25 05:45:00 |
|
2025-04-24 12:29:00 |
|
2025-04-24 09:00:00 |
|
2025-04-24 08:30:00 |
|
2025-04-24 05:45:00 |
|
2025-04-23 13:25:00 |
|
